About Us
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the benefit of humanity.
Oct 27, 2020...
REHOVOT, ISRAEL—October 27, 2020—Acute liver failure is a devastating, rapidly progressing disease that results in death in 80% of cases, unless an emergency liver transplant is performed. In the developed world, its leading cause is a substantial overdose of acetaminophen, also known as paracetamol.
In a study published in Nature Medicine, researchers from the labs of Prof. Eran Elinav and Prof. Ido Amit in the Weizmann Institute of Science’s Department of Immunology have, using mouse models of acute liver failure, discovered three liver-cell subsets that orchestrate the development of this condition. The scientists also identified signals – from the gut microbiome as well as the diseased liver – that jointly activate these cells, and showed that selectively blocking the signals and depleting the microbiome led to marked improvement in liver function and prolonged survival in the mice. An analysis of liver tissue from human patients with acute liver failure revealed a molecular pattern strikingly similar to the one identified in mice in the study, raising hopes that the findings may in the future be translated into a treatment for humans.
Oct 27, 2020...
A new study from the Weizmann Institute of Science, published in Nature Medicine, has found new subsets of cells and signals from the gut microbiome and the diseased liver that contribute to acute liver failure.
The researchers, who work in the labs of Profs. Eran Elinav and Ido Amit in the Immunology Department, hope that this and other research findings will contribute to new treatments for the condition.
https://www.weizmann-usa.org/news-media/news-releases/bacteria-may-aid-anti-cancer-immune-response/
Mar 17, 2021... REHOVOT, ISRAEL—March 17, 2021—Cancer immunotherapy may get a boost from an unexpected direction: bacteria residing within tumor cells. In a new study published in Nature, researchers at the Weizmann Institute of Science and their collaborators have discovered that the immune system “sees” these bacteria and shown that they can be harnessed to provoke an immune reaction against the tumor. The study may also help clarify the connection between immunotherapy and the gut microbiome, explaining the findings of previous research showing that the microbiome affects the success of immunotherapy.
Mar 17, 2021...
Cancer cells present bacterial peptides on the outside of their walls, marking them as a foreign element to the body’s immune system, Weizmann Institute scientists report in a new article published in Nature.
This is crucial as while immunotherapy has been able to help melanoma cancer patients in roughly 40% of cases, the new findings could pave the road to more effective treatments and many lives saved in the future.
Dec 08, 2021... REHOVOT, ISRAEL—December 8, 2021—Cigarette smoking, practiced by over a billion people worldwide, is considered a leading cause of disease, accounting for over six million deaths each year. Many people don’t quit smoking, despite expressing a desire to do so, because they are concerned about the substantial weight gain that often accompanies smoking cessation. The cause of this weight gain is unclear, as studies suggest that most people don’t eat more after quitting smoking. In a study published today in Nature, Weizmann Institute of Science researchers report discovering that obesity developing after “smoking cessation” in mice may be driven by the weight-modulating compounds released by their gut microbes.
©2022 American Committee for the Weizmann Institute of Science
